Acumen Pharma (NASDAQ: ABOS) files Form 144 for 3,530-share sale of stock

Rhea-AI Filing Summary

Acumen Pharmaceuticals, Inc. insider Russell Barton has filed a Form 144 notice to sell 3,530 shares of the company’s common stock through Merrill Lynch on the NASDAQ exchange. The planned sale has an aggregate market value of $6,561.55 and is against total common shares outstanding of 60,573,425.

The 3,530 shares were acquired on 01/06/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan, with payment recorded the same day. Over the prior three months, Barton sold additional Acumen common stock: 4,000 shares for $7,832.50 on 01/05/2026, 3,618 shares for $7,114.46 on 01/06/2026, and 1,700 shares for $3,378.00 on 01/07/2026.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	3530	6561.55	60573425	01/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/06/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			3530	01/06/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Russell Barton 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/05/2026	4000	7832.50
Russell Barton 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/06/2026	3618	7114.46
Russell Barton 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/07/2026	1700	3378.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Acumen Pharmaceuticals (ABOS) Form 144 filing disclose?

The Form 144 filing discloses that Russell Barton intends to sell 3,530 shares of Acumen Pharmaceuticals common stock on NASDAQ through Merrill Lynch, with an aggregate market value of $6,561.55.

How many Acumen Pharmaceuticals shares are being registered for potential sale?

The notice covers a proposed sale of 3,530 shares of Acumen Pharmaceuticals common stock, to be sold through Merrill Lynch on the NASDAQ exchange.

How did the seller acquire the 3,530 Acumen Pharmaceuticals shares?

The 3,530 shares were acquired on 01/06/2026 via the vesting of a restricted stock unit award granted as part of Acumen Pharmaceuticals’ equity compensation plan.

What Acumen Pharmaceuticals insider sales occurred in the past 3 months?

In the past 3 months, Russell Barton sold Acumen common stock in three transactions: 4,000 shares for $7,832.50 on 01/05/2026, 3,618 shares for $7,114.46 on 01/06/2026, and 1,700 shares for $3,378.00 on 01/07/2026.

How many Acumen Pharmaceuticals shares are outstanding in this Form 144?

The Form 144 states that Acumen Pharmaceuticals has 60,573,425 shares of common stock outstanding.

Which broker and exchange are used for the planned Acumen Pharmaceuticals share sale?

The planned sale of 3,530 shares will be executed through Merrill Lynch on the NASDAQ stock exchange.

What representation does the seller make in the Form 144 notice?

The seller represents that they do not know any material adverse information about Acumen Pharmaceuticals’ current or prospective operations that has not been publicly disclosed.